???global.info.a_carregar???
Dr Link is a CSIC researcher at the Sols-Morreale Biomedical Research Institute (IIBM, CSIC-UAM) focused on drug resistance mechanisms in cancer. He is also group leader at the Algarve Biomedical Center Research Institute (ABC-RI), and holds a position as an invited assistant professor at the Faculdade de Medicina e Ciências Biomédicas (FMBC) at the Universidade do Algarve (UAlg) in Faro and professor honorário at the Universidad Autónoma, Madrid (UAM). He is co-founder of Refoxy Pharma GMBH, Berlin/Boston, a biotech company dedicated to target FOXO proteins (www.refoxy.com). Dr Link counts with more than 25 years of experience in basic and translational biomedical research. He holds three patents (one licensed to Sanofi), published three books, three book chapters and over 90 articles (4 more under revision), 11 as first author, over 50 as senior author. He published articles (selection) in Nature, Oncogene, PNAS, Nature Reviews Drug Discovery, Trends in Biotechnology, EMBO J, The Lancet Oncology, Trends in Pharmacological Sciences, Drug Resistance Updates and Aging Cell. His work has been cited 7152 times. He also serves as an editorial board member of international peer reviewed journals. Dr Link built an extensive network of contacts and collaborations (member of three COST actions, majority of published papers from the Link lab include national and international collaborators). He has a proven track-record in drug discovery and drug development and has recently published a textbook on that topic (Link W. Springer Nature 2019). Dr Link acts as an expert evaluator for funding organisations including ERC (EU), The Brain Tumour Charity (UK), Leuka (UK), Dutch Cancer Society (Netherlands), Austrian Science Fund (ASF, Austria), ANEP (Spain), FCT (Portugal), MOH, AIFA (Italy), University of Macau (China), HRC (New Zealand), Université de Lille (France). He also serves as a peer-reviewer for (selection) Carcinogenesis, Chemical Reviews, Drug Discovery Today, FEBS Letters, Hepatology, International Journal of Cancer, J Cell Science, Nature Chemical Biology, Nature Comm., Oncogene, PloS ONE, PNAS, Scientific Reports, Trends in Cell Biology. Importantly, the Link group was one of the first to identify CRM1 inhibitors and ever since was on the forefront of CRM1 drug discovery. He identified TRIB2 as an oncogene involved in therapy resistance. Dr Link obtained his PhD degree from the University of Hamburg, followed by a postdoc at CNB, Madrid before joining the pharma company EleGene AG (Germany) as a senior scientist. In 2001, he moved to Madrid joining the newly-founded CNIO where he was promoted to head the screening group in 2010. In 2009 he co-founded the Madrid-based biotech company exCELLerate S.L. In 2012, he accepted a position as an assistant professor at the UAlg, Faro, Portugal where he was head of the Department of Oncobiology and co-director of the Masters program on Molecular mechanisms of cancer. In 2018, he also joined the Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM) in Madrid, Spain as a CSIC researcher and group leader. Five greatest contributions to science: 1. Cloning of Arg3.1/ARC, one of the most important genes in neuroscience and synaptic plasticity (Proc. Natl. Acad. Sci. USA 92, 5734-5738. doi: 10.1073/pnas.92.12.5734) 2. Cloning of DREAM, the first transcription factor directly regulated by calcium (Nature, 398, 80-84. doi: 10.1038/18044) 3. Identifying genetic and pharmacological means to activate FOXO transcription factors considered as key tumor suppressors and longevity genes (Nature Reviews Drug Discovery 20, 21-38. doi: 10.1038/s41573-020-0088-2) 4. Characterizing TRIB2 as an oncogene in Melanoma that confers therapy resistance (Oncogene 29, :2973-82. doi: 10.1038/onc.2010.58) 5. Generating high content screening (HCS) technology to identify CRM1 inhibitors (Trends Biotechnol. 28, 237-245. (Title story + Cover art) doi: 10.1016/j.tibt
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Wolfgang Link

Nomes de citação

  • Link, Wolfgang

Identificadores de autor

Ciência ID
6910-952E-242A
ORCID iD
0000-0002-3340-5165
Google Scholar ID
http://scholar.google.com/citations?hl=de&user=wPAcB10AAAAJ
Researcher Id
F-4435-2012
Scopus Author Id
35368713800

Websites

Domínios de atuação

  • Ciências Médicas e da Saúde - Biotecnologia Médica
  • Ciências Naturais - Ciências Biológicas - Biologia Celular
  • Ciências Naturais - Ciências Biológicas - Biologia
  • Ciências Naturais - Ciências Biológicas - Biologia Molecular
  • Ciências Médicas e da Saúde - Medicina Clínica - Oncologia

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Alemão (Idioma materno)
Inglês Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Espanhol; Castelhano Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Português Utilizador independente (B2) Utilizador independente (B2) Utilizador independente (B1) Utilizador independente (B1) Utilizador independente (B1)
Formação
Grau Classificação
2000/03/15 - 2001/01/31
Concluído
 Centro Nacional de Biotechnologia (CNB) (Postgraduate Certificate)
Consejo Superior de Investigaciones Científicas, Espanha
1995/04/01 - 2000/03/14
Concluído
 Universität Hamburg (Doktor (PhD))
Universität Hamburg, Alemanha
"Molekulare und funktionelle Charakterisierung des transkriptionellen repressors DREAM" (TESE/DISSERTAÇÃO)
1994/04/01 - 1995/03/31
Concluído
 Diploma thesis (Master)
Universitätsklinikum Hamburg-Eppendorf Zentrum für Molekulare Neurobiologie Hamburg, Alemanha
"Die somatodentritische Expression eines bisher unbekannten, unmittelbar frühen gens wird durch synaptische Aktivität reguliert" (TESE/DISSERTAÇÃO)
1987/04/01 - 1994/03/31
Concluído
 Study of Biology (Licence)
Universität Hamburg Department Biologie, Alemanha
Percurso profissional

Ciência

Categoria Profissional
Instituição de acolhimento 		Empregador
2011/12/01 - Atual Investigador principal (carreira) (Investigação) Universidade do Algarve - Campus de Gambelas, Portugal
Universidade do Algarve Centro de Investigação em Biomedicina, Portugal
2010/11/01 - 2011/11/30 Investigador principal (carreira) (Investigação) Centro Nacional de Investigaciones Oncológicas, Espanha
2001/09/01 - 2010/10/31 Investigador (Investigação) Centro Nacional de Investigaciones Oncológicas, Espanha
2000/10/01 - 2001/08/31 Investigador principal (carreira) (Investigação) Elegene GMBH, Alemanha

Docência no Ensino Superior

Categoria Profissional
Instituição de acolhimento 		Empregador
2021/01/01 - Atual Monitor (Docente Universitário) Fundación de la Universidad Autónoma de Madrid, Espanha
Fundación de la Universidad Autónoma de Madrid, Espanha
2018/07/31 - Atual Professor Auxiliar Convidado (Docente Universitário) Universidade do Algarve - Campus de Gambelas, Portugal
2013 - 2018 Professor Auxiliar (Docente Universitário) Universidade do Algarve, Portugal

Cargos e Funções

Categoria Profissional
Instituição de acolhimento 		Empregador
2013 - 2018 Conselho científico/técnico-científico ou orgão correspondente Universidade do Algarve, Portugal

Outros

Categoria Profissional
Instituição de acolhimento 		Empregador
2020/12/01 - Atual Biotech Company Rexoxy Pharmaceuticals, GMBH, Alemanha
2009/04/01 - 2011/06/06 Biotech Company exCELLerate S.L., , Espanha
Projetos

Bolsa

Designação Financiadores
2021/04/01 - Atual ENDURING- Desvendar mecanismos de resistência em Glioblastoma
PTDC/MED-ONC/4167/2020-
 Fundação para a Ciência e a Tecnologia
2021 - Atual Unravel resistance mechanisms in glioblastoma
PTDC/MED-ONC/4167/2020
Universidade do Algarve, Portugal
 Fundação para a Ciência e a Tecnologia
Em curso
2023/09/01 - 2026/08/31 Characterizing and modulating the Tribbles/ AKT/FOXO axis in melanoma (TAFmelanoma)
PID2022-136654OB-I00
Investigador responsável
Instituto de Investigaciones Biomédicas Sols-Morreale, Espanha
Em curso
2019/09 - 2021/09 Targeting TRIB2-mediated drug resistance in melanoma (RESIST)
RTI2018-094629-B-I00
Investigador responsável
Gobierno de España Ministerio de Ciencia Innovación y Universidades
Concluído
2019/09 - 2020/08 Superar la resistencia a medicamentos en glioma
EIN2019-103159
Investigador responsável
Gobierno de España Ministerio de Ciencia Innovación y Universidades
Concluído
2019/04/01 - 2020/03/31 Using natural products from regional grapes/wine capable of regulating FOXO factors as potential anti-aging drugs
CBMR Synergy Grant 2019
Investigador responsável
Concluído
2017/09/01 - 2020/03/31 RED transfronteriza para el desarrollo de productos innovadores con microALGAs
0055 ALGARED+
Investigador
Concluído
2018/12/01 - 2019/11/30 Characterization of therapy-induced stabilization of the drug resistance protein TRIB2
Intermural CSIC grannt
Investigador responsável
Consejo Superior de Investigaciones Científicas, Espanha
Concluído
2017/02/01 - 2018/01/31 Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitiors in the context of melanoma
LPCC-NRS/Terry Fox 2017-2018
Co-Investigador Responsável (Co-IR)
Liga Portuguesa Contra o Cancro
Concluído
2016/04/01 - 2017/03/31 Characterizing of TRIB-mediated resistance to anti-melanoma drugs
LPCC-NRS/Terry Fox 2016-2017
Investigador responsável
Concluído
2015/06/01 - 2016/05/31 Role of TRIB2 in the progression of Breast Cancer
Bolsa Laço 2015
Investigador responsável
Universidade do Algarve - Campus de Gambelas, Portugal
Concluído
2014/03/01 - 2015/02/28 Impact of FOXO activators on aging
NIH U19 AG023122
Co-Investigador Responsável (Co-IR)
National Institutes of Health
Concluído
2013/04 - 2014/03 The role of tribbles homolog 2 (TRIB2) in drug resistance (e.g. to BAY 80-6946, and BAY 1082439, BAY 1001931 and BAY 86-9766) andits potential use as a biomarker to predict resistance to PI3K/Akt and MEK inhibitors
Grant4Target 2013
Investigador responsável
Bayer Corp
Concluído
2006/09/01 - 2009/08/31 Identificación de compuestos líder y dianas terapéuticas: Utilización de la vía de PI3K/Akt para el descubrimiento de compuestos anticancerígenos
BIO2006-02432
Investigador responsável
Gobierno de España
Concluído
2002/03/01 - 2005/02/28 Desarrollo de ensayos celulares basados en la vía PI3’K/Akt para el descubrimiento de moléculas líder con potencial antitumoral
BIO2002-00197
Investigador responsável
Gobierno de España
Concluído

Projeto

Designação Financiadores
2020/12/01 - Atual Developing small molecule FOXO activator compounds to treat age-related diseases and promote healthy aging
R&D Apollo
Orientador
Em curso
2019/01/01 - 2020/03/31 Centre for Biomedical Research
UID/BIM/04773/2019
Universidade do Algarve, Portugal

Universidade do Algarve Centro de Investigação em Biomedicina, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
Produções

Publicações

Artigo em revista
  1. Bruno F. Santos; Inês Grenho; Paulo J. Martel; Bibiana I. Ferreira; Wolfgang Link. "FOXO family isoforms". Cell Death & Disease (2023): https://doi.org/10.1038/s41419-023-06177-1.
    10.1038/s41419-023-06177-1
  2. Guillermo Velasco; Wolfgang Link. "Pseudokinases, Tribbles Proteins and Cancer". Cancers (2023): https://doi.org/10.3390/cancers15143547.
    10.3390/cancers15143547
  3. De Sousa-Coelho, Ana Luísa; Gacias, Mar; O'Neill, Brian T.; Relat, Joana; Link, Wolfgang; Haro, Diego; Marrero, Pedro F.. "FOXO1 represses PPARa-Mediated induction of FGF21 gene expression". Biochemical and Biophysical Research Communications 644 (2023): 122-129. http://dx.doi.org/10.1016/j.bbrc.2023.01.012.
    10.1016/j.bbrc.2023.01.012
  4. Orea-Soufi, Alba; Paik, Jihye; Bragança, José; Donlon, Timothy A.; Willcox, Bradley J.; Link, Wolfgang. "FOXO transcription factors as therapeutic targets in human diseases". Trends in Pharmacological Sciences 43 12 (2022): 1070-1084. http://dx.doi.org/10.1016/j.tips.2022.09.010.
    10.1016/j.tips.2022.09.010
  5. Jimenez, Lucia; Mayoral-Varo, Victor; Amenábar, Carlos; Ortega, Judit; Sequeira, João G. N.; Machuqueiro, Miguel; Mourato, Cristiana; et al. "Multiplexed cellular profiling identifies an organoselenium compound as an inhibitor of CRM1 -mediated nuclear export". Traffic 23 12 (2022): 587-599. http://dx.doi.org/10.1111/tra.12872.
    10.1111/tra.12872
  6. De Sousa-Coelho, Ana Luísa; Aureliano, Manuel; Fraqueza, Gil; Serrão, Gisela; Gonçalves, João; Sánchez-Lombardo, Irma; Link, Wolfgang; Ferreira, Bibiana I.. "Decavanadate and metformin-decavanadate effects in human melanoma cells". Journal of Inorganic Biochemistry 235 (2022): 111915. http://dx.doi.org/10.1016/j.jinorgbio.2022.111915.
    10.1016/j.jinorgbio.2022.111915
  7. Lucia Jimenez; Carlos Amenabar; Victor; Thomas A. Mackenzie; Carmen Ramos; Andreia Silva; Giampaolo Calissi; et al. "mTORC2 Is the Major Second Layer Kinase Negatively Regulating FOXO3 Activity". Molecules (2022): https://www.mdpi.com/1420-3049/27/17/5414.
    10.3390/molecules27175414
  8. Slavchev, Ivaylo M.; Mitrev, Yavor; Shivachev, Boris; Valcheva, Violeta; Dogonadze, Marine; Solovieva, Natalia; Vyazovaya, Anna; et al. "Synthesis, Characterization and Complex Evaluation of Antibacterial Activity and Cytotoxicity of New Arylmethylidene Ketones and Pyrimidines with Camphane Skeletons". ChemistrySelect 7 17 (2022): http://dx.doi.org/10.1002/slct.202201339.
    10.1002/slct.202201339
  9. Passirani, Catherine; Vessières, Anne; La Regina, Giuseppe; Link, Wolfgang; Silvestri, Romano. "Modulating undruggable targets to overcome cancer therapy resistance". Drug Resistance Updates 60 (2022): 100788. http://dx.doi.org/10.1016/j.drup.2021.100788.
    10.1016/j.drup.2021.100788
  10. Faleiro, Inês; Roberto, Vânia Palma; Demirkol Canli, Secil; Fraunhoffer, Nicolas A.; Iovanna, Juan; Gure, Ali Osmay; Link, Wolfgang; Castelo-Branco, Pedro. "DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study". Cancers 13 24 (2021): 6354. http://dx.doi.org/10.3390/cancers13246354.
    10.3390/cancers13246354
  11. Mónica T. Fernandes; Victor Yassuda; José Bragança; Wolfgang Link; Bibiana I. Ferreira; Ana Luísa De Sousa-Coelho. "Tribbles Gene Expression Profiles in Colorectal Cancer". Gastrointestinal Disorders 3 4 (2021): 218-236. https://doi.org/10.3390/gidisord3040021.
    10.3390/gidisord3040021
  12. Jimenez, Lucia; Silva, Andreia; Calissi, Giampaolo; Grenho, Inês; Monteiro, Rita; Mayoral-Varo, Victor; Blanco-Aparicio, Carmen; et al. "Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3". The Journals of Gerontology: Series A (2021): http://dx.doi.org/10.1093/gerona/glab265.
    Publicado • 10.1093/gerona/glab265
  13. Link, Wolfgang; Ilardi, Gennaro; Zannetti, Antonella. "Editorial: Tumor Microenvironment: Molecular Mechanisms and Signaling Pathways Involved in Metastatic Progression". Frontiers in Oncology 11 (2021): http://dx.doi.org/10.3389/fonc.2021.730815.
    Publicado • 10.3389/fonc.2021.730815
  14. Bibiana I. Ferreira; Bruno Santos; Wolfgang Link; Ana Luísa De Sousa-Coelho. "Tribbles Pseudokinases in Colorectal Cancer". Cancers 13 11 (2021): 2825-2825. https://doi.org/10.3390/cancers13112825.
    10.3390/cancers13112825
  15. Victor Mayoral-Varo; Lucía Jiménez; Wolfgang Link. "The Critical Role of TRIB2 in Cancer and Therapy Resistance". Cancers (2021): https://doi.org/10.3390/cancers13112701.
    10.3390/cancers13112701
  16. Pérez-Beltrán, Christian Hazael; García-Guzmán, Juan José; Ferreira, Bibiana; Estévez-Hernández, Osvaldo; López-Iglesias, David; Cubillana-Aguilera, Laura; Link, Wolfgang; et al. "One-minute and green synthesis of magnetic iron oxide nanoparticles assisted by design of experiments and high energy ultrasound: Application to biosensing and immunoprecipitation". Materials Science and Engineering: C (2021): 112023. http://dx.doi.org/10.1016/j.msec.2021.112023.
    Acesso aberto • 10.1016/j.msec.2021.112023
  17. Kalpana N. Handore; Vasant V. Chabukswar; Digamber Pawar; Sabrina Dallavalle. "Ultrasound-assisted solvent-free synthesis of 3, 4-dihydropyrimidin-2(1H)-ones/thiones using polyindole as a recyclable catalyst". Polymer-Plastics Technology and Materials 60 3 (2021): 306-315. https://doi.org/10.1080/25740881.2020.1811313.
    10.1080/25740881.2020.1811313
  18. Giampaolo Calissi; Eric W.-F. Lam; Wolfgang Link. "Therapeutic strategies targeting FOXO transcription factors". Nature Reviews Drug Discovery (2021): https://doi.org/10.1038/s41573-020-0088-2.
    10.1038/s41573-020-0088-2
  19. Santos, Bruno F; Link, Wolfgang; Ferreira, Bibiana I.; Grenho, Inês. "FOXO Isoforms in Cancer: Beyond classic bona fide tumor suppressors. (work in progress)". (2021):
  20. Machado S; Andreia Silva; Ana Luísa De Sousa-Coelho; Isabel Duarte; Inês Grenho; Bruno Santos; Victor Mayoral-Varo; et al. "Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance". Cancers (2020): https://www.mdpi.com/2072-6694/12/12/3689.
    10.3390/cancers12123689
  21. Ferreira, Bibiana I.; Cautain, Bastien; Grenho, Inês; Link, Wolfgang. "Small Molecule Inhibitors of CRM1". Frontiers in Pharmacology 11 (2020): http://dx.doi.org/10.3389/fphar.2020.00625.
    10.3389/fphar.2020.00625
  22. Link, Wolfgang. "CRISPR/Cas9-mediated genome editing: From basic research to translational medicine". Journal of Cellular and Molecular Medicine (2020): http://dx.doi.org/10.1111/jcmm.14916.
    10.1111/jcmm.14916
  23. Cui, Bing; Eyers, Patrick A.; Dobens, Leonard L.; Tan, Nguan Soon; Mace, Peter D.; Link, Wolfgang; Kiss-Toth, Endre; et al. "Highlights of the 2nd international symposium on tribbles and diseases: tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer". (2019): http://hdl.handle.net/10400.1/12538.
    10.1016/j.apsb.2018.12.007
  24. Henriques, V.; Martins, T.; Link, W.; Ferreira, B.I.. "The emerging therapeutic landscape of advanced melanoma". Current Pharmaceutical Design 24 5 (2018): 549-558. http://www.scopus.com/inward/record.url?eid=2-s2.0-85049050742&partnerID=MN8TOARS.
    10.2174/1381612824666180125093357
  25. Link, W.. "Knowledge-based drug discovery intensifies private appropriation of publicly financed research". The Lancet Oncology 19 8 (2018): 1017-1018. http://www.scopus.com/inward/record.url?eid=2-s2.0-85050801734&partnerID=MN8TOARS.
    10.1016/S1470-2045(18)30437-6
  26. Wolfgang Link; Pablo J. Fernandez-Marcos. "FOXO transcription factors at the interface of metabolism and cancer". International Journal of Cancer 141 12 (2017): 2379-2391. https://doi.org/10.1002/ijc.30840.
    10.1002/ijc.30840
  27. Link W. "Immunology: Mind the immuno-connection gap.". (2017): http://europepmc.org/abstract/med/28437396.
    10.1038/nchembio.2373
  28. Ferreira, B.I.; Lie, M.K.; Engelsen, A.S.T.; Machado, S.; Link, W.; Lorens, J.B.. "Adaptive mechanisms of resistance to anti-neoplastic agents". MedChemComm 8 1 (2017): 53-66. http://www.scopus.com/inward/record.url?eid=2-s2.0-85010716209&partnerID=MN8TOARS.
    10.1039/c6md00394j
  29. Martins R; Lithgow GJ; Link W. "Long live FOXO: unraveling the role of FOXO proteins in aging and longevity.". (2016): http://europepmc.org/abstract/med/26643314.
    10.1111/acel.12427
  30. Cautain B; Castillo F; Musso L; Ferreira BI; de Pedro N; Rodriguez Quesada L; Machado S; et al. "Discovery of a Novel, Isothiazolonaphthoquinone-Based Small Molecule Activator of FOXO Nuclear-Cytoplasmic Shuttling.". (2016): http://europepmc.org/abstract/med/27936162.
    10.1371/journal.pone.0167491
  31. Tarrado-Castellarnau M; Cortés R; Zanuy M; Tarragó-Celada J; Polat IH; Hill R; Fan TW; Link W; Cascante M. "Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition.". (2015): http://europepmc.org/abstract/med/26375988.
    10.1016/j.phrs.2015.09.009
  32. Hill R; Kalathur RK; Colaço L; Brandão R; Ugurel S; Futschik M; Link W; et al. "TRIB2 as a biomarker for diagnosis and progression of melanoma.". Biochemical Society Transactions 43 (2015): 1085-1088. http://europepmc.org/abstract/med/25586991.
    10.1093/carcin/bgv002
  33. Wolfgang Link. "Molecular Inhibitors in Targeted Therapy". Molecular inhibitors in targeted therapy 1 1 (2015): https://doi.org/10.1515%2Fmotth-2015-0001.
    10.1515/motth-2015-0001
  34. Cautain, B.; Hill, R.; De Pedro, N.; Link, W.. "Components and regulation of nuclear transport processes". FEBS Journal 282 3 (2015): 445-462. http://www.scopus.com/inward/record.url?eid=2-s2.0-84921797642&partnerID=MN8TOARS.
    10.1111/febs.13163
  35. Ferreira, B.I.; Hill, R.; Link, W.. "Caught in the crosshairs: Targeted drugs and personalized medicine". Cancer Journal (United States) 21 6 (2015): 441-447. http://www.scopus.com/inward/record.url?eid=2-s2.0-84948411505&partnerID=MN8TOARS.
  36. Ferreira BI; Hill R; Link W. "Special Review: Caught in the Crosshairs: Targeted Drugs and Personalized Medicine.". (2015): http://europepmc.org/abstract/med/26588674.
    10.1097/ppo.0000000000000161
  37. Tarrado-Castellarnau, Miriam; Cortes, Roldan; Zanuy, Miriam; Tarrago-Celada, Josep; Polat, Ibrahim H.; Hill, Richard; Fan, Teresa W. M.; Link, Wolfgang; Cascante, Marta. "Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition". (2015): http://hdl.handle.net/10400.1/11207.
    https://doi.org/10.1016/j.phrs.2015.09.009
  38. Hill, Richard; Kalathur, Ravi Kiran Reddy; Callejas, Sergio; Colaço, Laura; Brandão, Ricardo; Serelde, Beatriz; Cebriá, Antonio; et al. "A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes". Breast Cancer Research 16 6 (2014): http://dx.doi.org/10.1186/s13058-014-0482-y.
    10.1186/s13058-014-0482-y
  39. Hill, R.; Cautain, B.; De Pedro, N.; Link, W.. "Targeting nucleocytoplasmic transport in cancer therapy". Oncotarget 5 1 (2014): 11-28. http://www.scopus.com/inward/record.url?eid=2-s2.0-84893870810&partnerID=MN8TOARS.
    10.18632/oncotarget.1457
  40. Mori, Mattia; Vignaroli, Giulia; Cau, Ylenia; Dinic, Jelena; Hill, Richard; Rossi, Matteo; Colecchia, David; et al. "Discovery of 14-3-3 Protein- Protein Interaction Inhibitors that Sensitize Multidrug- Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693". Chemmedchem 9 5 (2014): 973-983.
    10.1002/cmdc.201400044
  41. Cortés, Roldán; Tarrado-Castellarnau, Míriam; Talancón, Daniel; López, Concepción; Link, Wolfgang; Ruiz, Daniel; Centelles, Josep Joan; Quirante, Josefina; Cascante, Marta. "A novel cyclometallated Pt(ii)–ferrocene complex induces nuclear FOXO3a localization and apoptosis and synergizes with cisplatin to inhibit lung cancer cell proliferation". Metallomics 6 3 (2014): 622. http://dx.doi.org/10.1039/c3mt00194f.
    10.1039/c3mt00194f
  42. Cautain, Bastien; de Pedro, Nuria; Murillo Garzón, Virginia; Muñoz de Escalona, María; González Menéndez, Victor; Tormo, José R.; Martin, Jesús; et al. "High-Content Screening of Natural Products Reveals Novel Nuclear Export Inhibitors". Journal of Biomolecular Screening 19 1 (2013): 57-65. http://dx.doi.org/10.1177/1087057113501389.
    10.1177/1087057113501389
  43. Link Wolfgang; Madureira Patricia; Hill Richard. "Identifying new targets for personalized medicine". eLS. John Wiley & Sons, Ltd: Chichester (2013):
    DOI: 10.1002/9780470015902.a0024865
  44. Granda, T.G.; Cebrián, D.; Martínez, S.; Anguita, P.V.; López, E.C.; Link, W.; Merino, T.; et al. "Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases". Investigational New Drugs 31 1 (2013): 66-76. http://www.scopus.com/inward/record.url?eid=2-s2.0-84873832557&partnerID=MN8TOARS.
    10.1007/s10637-012-9835-5
  45. Evensen, L.; Link, W.; Lorens, J.B.. "Image-based high-throughput screening for inhibitors of angiogenesis.". Methods in molecular biology (Clifton, N.J.) 931 (2013): 139-151. http://www.scopus.com/inward/record.url?eid=2-s2.0-84873518972&partnerID=MN8TOARS.
  46. Zanella, F.; dos Santos, N.R.; Link, W.. "Moving to the Core: Spatiotemporal analysis of forkhead Box O (FOXO) and nuclear factor-¿B (NF-¿B) nuclear translocation". Traffic 14 3 (2013): 247-258. http://www.scopus.com/inward/record.url?eid=2-s2.0-84873424232&partnerID=MN8TOARS.
    10.1111/tra.12034
  47. Wolfgang Link. "Nuclear accumulation of ß-catenin and forkhead box O3a in colon cancer: Dangerous liaison". World Journal of Biological Chemistry 3 9 (2012): 175-175. https://doi.org/10.4331%2Fwjbc.v3.i9.175.
    10.4331/wjbc.v3.i9.175
  48. Kauselmann, G.; Dopazo, A.; Link, W.. "Identification of disease-relevant genes for molecularly-targeted drug discovery". Current Cancer Drug Targets 12 1 (2012): 1-13. http://www.scopus.com/inward/record.url?eid=2-s2.0-84855851646&partnerID=MN8TOARS.
    10.2174/156800912798888947
  49. Martínez González, S.; Hernández, A.I.; Varela, C.; Rodríguez-Arístegui, S.; Lorenzo, M.; Rodríguez, A.; Rivero, V.; et al. "Identification of ETP-46321, a potent and orally bioavailable PI3K a, d inhibitor". Bioorganic and Medicinal Chemistry Letters 22 10 (2012): 3460-3466. http://www.scopus.com/inward/record.url?eid=2-s2.0-84860467003&partnerID=MN8TOARS.
    10.1016/j.bmcl.2012.03.090
  50. Martinez Gonzalez, Sonia; Isabel Hernandez, Ana; Varela, Carmen; Rodriguez-Aristegui, Sonsoles; Maria Alvarez, Rosa; Belen Garcia, Ana; Lorenzo, Milagros; et al. "Imidazo 1,2-a pyrazines as novel PI3K inhibitors". Bioorganic & Medicinal Chemistry Letters 22 5 (2012): 1874-1878.
    10.1016/j.bmcl.2012.01.074
  51. Martinez Gonzalez, Sonia; Isabel Hernandez, Ana; Varela, Carmen; Lorenzo, Milagros; Ramos-Lima, Francisco; Cendon, Elena; Cebrian, David; et al. "Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR". Bioorganic & Medicinal Chemistry Letters 22 16 (2012): 5208-5214.
    10.1016/j.bmcl.2012.06.093
  52. Link, W.. "Editorial". Current Drug Targets 12 9 (2011): 1232-1234. http://www.scopus.com/inward/record.url?eid=2-s2.0-79960000513&partnerID=MN8TOARS.
    10.2174/138945011796150235
  53. Link, Wolfgang. "Context-dependent therapeutic potential of FOXO proteins in oral squamous cell carcinoma". Oral Oncology 47 4 (2011): 229-230.
    10.1016/j.oraloncology.2011.02.008
  54. Hung, Mien-Chie; Link, Wolfgang. "Protein localization in disease and therapy". Journal of Cell Science 124 20 (2011): 3381-3392.
    10.1242/jcs.089110
  55. Zanella, F.; Link, W.; Carnero, A.. "Understanding FOXO, new views on old transcription factors". Current Cancer Drug Targets 10 2 (2010): 135-146. http://www.scopus.com/inward/record.url?eid=2-s2.0-77950680198&partnerID=MN8TOARS.
    10.2174/156800910791054158
  56. Evensen, Lasse; Micklem, David R.; Link, Wolfgang; Lorens, James B.. "A Novel Imaging-based High-throughput Screening Approach to Anti-angiogenic Drug Discovery". Cytometry Part a 77A 1 (2010): 41-51.
    10.1002/cyto.a.20808
  57. Pastor, J.; Martinez, S.; Alvarez, R. M.; Varela, C.; Hernandez, A. I.; Rodriguez, S.; Oyarzabal, J.; et al. "Amino-alkyl substituted fused imidazoles: potent, selective and orally bioavailable inhibitors of PI3K". Ejc Supplements 8 7 (2010): 62-62.
    10.1016/S1359-6349(10)71888-7
  58. Zanella, F.; Renner, O.; Garcia, B.; Callejas, S.; Dopazo, A.; Peregrina, S.; Carnero, A.; Link, W.. "Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells". Oncogene 29 20 (2010): 2973-2982.
    10.1038/onc.2010.58
  59. Evensen, Lasse; Link, Wolfgang; Lorens, James B.. "Imaged-based High-Throughput Screening for Anti-Angiogenic Drug Discovery". Current Pharmaceutical Design 16 35 (2010): 3958-3963.
    10.2174/138161210794455030
  60. Rabal, Obdulia; Link, Wolfgang; Serelde, Beatriz G.; Bischoff, James R.; Oyarzabal, Julen. "An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries". Molecular Biosystems 6 4 (2010): 711-720.
    10.1039/b919830j
  61. Zanella, Fabian; Lorens, James B.; Link, Wolfgang. "High content screening: seeing is believing". Trends in Biotechnology 28 5 (2010): 237-245.
    10.1016/j.tibtech.2010.02.005
  62. Link, W.. "Exploring the biological space of FOXO regulation: discovery of therapeutic targets and small molecule inhibitors for anticancer therapy". New Biotechnology 25 (2009): S3-S3.
    10.1016/j.nbt.2009.06.010
  63. Zanella, Fabian; Rosado, Aranzazu; Garcia, Beatriz; Carnero, Amancio; Link, Wolfgang. "Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators". Bmc Cell Biology 10 (2009):
    10.1186/1471-2121-10-14
  64. Link, Wolfgang; Oyarzabal, Julen; Serelde, Beatriz G.; Isabel Albarran, Maria; Rabal, Obdulia; Cebria, Antonio; Alfonso, Patricia; et al. "Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases". Journal of Biological Chemistry 284 41 (2009): 28392-28400.
    10.1074/jbc.M109.038984
  65. Carnero, Amancio; Blanco-Aparicio, Carmen; Renner, Oliver; Link, Wolfgang; Leal, Juan F. M.. "The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications". Current Cancer Drug Targets 8 3 (2008): 187-198.
    10.2174/156800908784293659
  66. Rosado, Aranzazu; Zanella, Fabian; Garcia, Beatriz; Carnero, Amancio; Link, Wolfgang. "A Dual-Color Fluorescence-Based Platform to Identify Selective Inhibitors of Akt Signaling". Plos One 3 3 (2008):
    10.1371/journal.pone.0001823
  67. Zanella, Fabian; Rosado, Aranzazu; Garcia, Beatriz; Carnero, Amancio; Link, Wolfgang. "Chemical Genetic Analysis of FOXO Nuclear-Cytoplasmic Shuttling by Using Image-Based Cell Screening". Chembiochem 9 14 (2008): 2229-2237.
    10.1002/cbic.200800255
  68. Guijarro, Maria V.; Link, Wolfgang; Rosado, Aranzazu; Leal, Juan F. M.; Carnero, Amancio. "MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation". Carcinogenesis 28 12 (2007): 2443-2450.
    10.1093/carcin/bgm154
  69. Liebel, Urban; Link, Wolfgang. "Meeting report: trends and challenges in high content analysis.". Biotechnology journal 2 8 (2007): 938-40.
    10.1002/biot.200700101
  70. Zanella, Fabian; Rosado, Aranzazu; Blanco, Fernando; Henderson, Beric R.; Carnero, Amancio; Link, Wolfgang. "An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays". Assay and Drug Development Technologies 5 3 (2007): 333-341.
    10.1089/adt.2007.058
  71. Link, W; Rosado, A; Fominaya, J; Thomas, JE; Carnero, A. "Membrane localization of all class IPI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt". Journal of Cellular Biochemistry 95 5 (2005): 979-989.
    10.1002/jcb.20479
  72. Link, WA; Ledo, F; Torres, B; Palczewska, M; Madsen, TM; Savignac, M; Albar, JP; Mellstrom, B; Naranjo, JR. "Day-night changes in downstream regulatory element antagonist modulator/potassium channel interacting protein activity contribute to circadian gene expression in pineal gland". Journal of Neuroscience 24 23 (2004): 5346-5355.
    10.1523/JNEUROSCI.1460-04.2004
  73. Mellstrom, Britt; Torres, Begona; Link, Wolfgang A; Naranjo, Jose R. "The BDNF gene: exemplifying complexity in Ca2+ -dependent gene expression.". Critical reviews in neurobiology 16 1-2 (2004): 43-9.
    10.1615/CritRevNeurobiol.v16.i12.40
  74. Moneo, V; Guijarro, MD; Link, W; Carnero, A. "Overexpression of cyclin D1 inhibits TNF-induced growth arrest". Journal of Cellular Biochemistry 89 3 (2003): 484-499.
    10.1002/jcb.10529
  75. Carnero, A.; Blanco, C.; Blanco, F.; Castro, M.E.; Guijarro, M.V.; Fominaya, J.; Link, W.; et al. "Exploring cellular senescence as a tumor suppressor mechanism". Clinical and Translational Oncology 5 5 (2003): 249-265. http://www.scopus.com/inward/record.url?eid=2-s2.0-33646253025&partnerID=MN8TOARS.
  76. Sanz, C; Mellstrom, B; Link, WA; Naranjo, JR; Fernandez-Luna, JL. "Interleukin 3-dependent activation of DREAM is involved in transcriptional silencing of the apoptotic hrk gene in hematopoietic progenitor cells". Embo Journal 20 9 (2001): 2286-2292.
    10.1093/emboj/20.9.2286
  77. Ledo, F; Carrion, AM; Link, WA; Mellstrom, B; Naranjo, JR. "DREAM-alpha CREM interaction via leucine-charged domains derepresses downstream regulatory element-dependent transcription". Molecular and Cellular Biology 20 24 (2000): 9120-9126.
    10.1128/MCB.20.24.9120-9126.2000
  78. Link, WA; Kauselmann, G; Mellstrom, B; Kuhl, D; Naranjo, JR. "Induction of glycerol phosphate dehydrogenase gene expression during seizure and analgesia". Journal of Neurochemistry 75 4 (2000): 1419-1428.
    10.1046/j.1471-4159.2000.0751419.x
  79. Ledo, F; Link, WA; Carrion, AM; Echeverria, V; Mellstrom, B; Naranjo, JR. "The DREAM-DRE interaction: key nucleotides and dominant negative mutants". Biochimica Et Biophysica Acta-Molecular Cell Research 1498 2-3 (2000): 162-168.
    10.1016/S0167-4889(00)00092-6
  80. Carrión, A.M.; Link, W.A.; Ledo, F.; Mellström, B.; Naranjo, J.R.. "DREAM is a Ca2+-regulated transcriptional repressor". Nature 398 6722 (1999): 80-84. http://www.scopus.com/inward/record.url?eid=2-s2.0-0033521983&partnerID=MN8TOARS.
    10.1038/18044
  81. Carrion, A.M.; Taylor, J.S.; Link, W.; Morcuende, S.; Mellsrtrom, B.; Naranjo, J.R.. "Early gene induction and spinal cord function". DOLOR 11 1 (1996): 22-24. http://www.scopus.com/inward/record.url?eid=2-s2.0-0029960761&partnerID=MN8TOARS.
  82. LINK, W; KONIETZKO, U; KAUSELMANN, G; KRUG, M; SCHWANKE, B; FREY, U; KUHL, D. "SOMATODENDRITIC EXPRESSION OF AN IMMEDIATE-EARLY GENE IS REGULATED BY SYNAPTIC ACTIVITY". Proceedings of the National Academy of Sciences of the United States of America 92 12 (1995): 5734-5738.
    10.1073/pnas.92.12.5734
Entrada de dicionário
  1. Florindo, Claudia; Ferreira, Bibiana I; Serrão, Sónia M; Tavares, Álvaro A; Link, Wolfgang. "Subcellular Protein Localisation in Health and Disease". In eLS. John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9780470015902.a0026534.
    10.1002/9780470015902.a0026534
Livro
  1. Link, W.. Introduction to FOXO biology. 2019.
    10.1007/978-1-4939-8900-3_1
  2. Barradas, M.; Link, W.; Megias, D.; Fernandez-Marcos, P.J.. High-throughput image-based screening to identify chemical compounds capable of activating FOXO. 2019.
    10.1007/978-1-4939-8900-3_13
  3. Machado, S.; Raposo, C.; Ferreira, B.I.; Link, W.. Image-based identification of chemical compounds capable of trapping FOXO in the cell nucleus. 2019.
    10.1007/978-1-4939-8900-3_14
  4. Link, W.. Preface. 2019.
  5. Wolfgang Link. FOXO Transcription Factors. Springer New York. 2019.
    10.1007/978-1-4939-8900-3
  6. Henriques, V.; Machado, S.; Link, W.; Ferreira, B.I.. Monitoring the transcriptional activity of FOXO transcription factors by analyzing their target genes. 2019.
    10.1007/978-1-4939-8900-3_9
  7. Link, Wolfgang. Principles of Cancer Treatment and Anticancer Drug Development. 2019.
    10.1007/978-3-030-18722-4
  8. Cautain, B.; de Pedro, N.; Reyes, F.; Link, W.. Image-based identification of nuclear export inhibitors from natural products. 2015.
    10.1007/978-1-4939-2309-0_22
  9. Link, Wolfgang. International Manual of Oncology Practice. 2015.
    10.1007/978-3-319-21683-6
  10. Evensen, L.; Link, W.; Lorens, J.B.. Image-based high-throughput screening for inhibitors of angiogenesis. 2012.
    10.1007/978-1-62703-56-4_8
Poster em conferência
  1. Sequeira, João G. N.; Link, Wolfgang; Machuqueiro, Miguel. Autor correspondente: Sequeira, João G. N.. "Searching for CRM1 inhibitors using a HTVS protocol". Trabalho apresentado em 3D-BioInfo-PT annual meeting, 2022.
  2. Sequeira, João G. N.; Link, Wolfgang; Machuqueiro, Miguel. Autor correspondente: Sequeira, João G. N.. "High-throughput virtual screening to identify non-covalent inhibitors of CRM1 with anti-tumoral potential". Trabalho apresentado em 6ª Conferência Anual da RedeSAÚDE, 2022.
  3. Leite, Letícia P.; Orea-Soufi, Alba; Link, Wolfgang; Ferreira, Bibiana I.. "Knocking TRIB3 out: a model to study TRIB3 as a potential biomarker and target for glioblastoma therapy". Trabalho apresentado em iMED Conference - Innovate Competition, 2022.
  4. Sequeira, João G. N.; Link, Wolfgang; Machuqueiro, Miguel. Autor correspondente: Sequeira, João G. N.. "An ad hoc HTVS protocol to identify new CRM1 non-covalent inhibitors". Trabalho apresentado em 2nd Chem & BioChem Students Meeting, 2022.
  5. De Sousa-Coelho, Ana Luísa; Link, Wolfgang; Ferreira, Bibiana I.. "Tribbles gene expression in glioblastoma brain tumors". Trabalho apresentado em 5th ASPIC International Congress. IPO, Porto, Portugal, 2022.
  6. De Sousa-Coelho, Ana Luísa; Claro, Inês G.; Link, Wolfgang; Ferreira, Bibiana I.. "Potential role of TRIB2 in the treatment of melanoma with thiazolidinediones". Trabalho apresentado em Conference/Webinar - Cutaneous Melanoma: from where to where?, 2021.
  7. Ana Luisa De Sousa-Coelho; João Gonçalves; Gisela Serrão; Sánchez-Lombardo I; Manuel Aureliano; Link, Wolfgang; Ferreira, Bibiana I.. "Effects of pure and hybrid polyoxovanadates in human melanoma cancer cells.". Trabalho apresentado em II ASPIC-ASEICA International Meeting - Current Trends in Precision Medicine in Cancer, 2021.
  8. De Sousa-Coelho, Ana Luísa; Ferreira, Bibiana I.; Manuel Aureliano; Link, Wolfgang. "Tuning polyoxometalates complexes against melanoma.". Trabalho apresentado em Keystone Symposia on Tumor Metabolism and the Microenvironment, 2021.
  9. Claro, Inês G.; Pinto, Ana Patrícia; Ferreira, Bibiana I.; Link, Wolfgang; De Sousa-Coelho, Ana Luísa. "Avaliação do risco/benefício da terapia com antidiabéticos orais ¿ o caso das biguanidas e das tiazolidinedionas na progressão do melanoma na diabetes.". Trabalho apresentado em 16º Congresso Português de Diabetes ¿ Vilamoura (Portugal), 2020.
  10. Varela, Miriam; Ferreira, Bibiana I.; Link, Wolfgang; De Sousa-Coelho, Ana Luísa. "Modulation of the Tribbles family members through hypoxia.". Trabalho apresentado em Cancer Biology: From basic to translational research. Webminar (Liga Portuguesa Contra o Cancro), 2020.
  11. De Sousa-Coelho, Ana Luísa; Claro, Inês; Ferreira, Bibiana I.; Link, Wolfgang. "TRI(B)pping over Rosiglitazone: Exploring the role of thiazolidinediones in melanoma.". Trabalho apresentado em III Poster Sunset Session ¿ ESSUAlg 2019, 2019.
  12. De Sousa-Coelho, Ana Luísa; Rodrigues-Viegas, Vanessa; Link, Wolfgang. "TRIB2 Gene Expression in Brown Adipose Tissue.". Trabalho apresentado em 3ªs Jornadas Algarve Biomedical Center, 2019.
  13. De Sousa-Coelho, Ana Luísa; Barbosa-Mota, Júlio; Link, Wolfgang. "A expressão renal de TRIB2 encontra-se reduzida na nefropatia diabética.". Trabalho apresentado em 3ªs Jornadas Algarve Biomedical Center, 2019.
  14. De Sousa-Coelho, Ana Luísa; Link, Wolfgang. "TRIB2 expression in fat is negatively associated with insulin sensitivity.". Trabalho apresentado em 10th Meeting on Signal Transduction (SINAL 2019), Olhão (Portugal), 2019.
  15. Rodrigues-Viegas, Vanessa; Machado, Susana; Ferreira, Bibiana I.; Link, Wolfgang; De Sousa-Coelho, Ana Luísa. "TRI(B)pping Over Metabolism: Exploring the Role of TRIB2 in Metabolic Tissues.". Trabalho apresentado em II Poster Sunset Session ¿ ESSUAlg 2018. Faro (Portugal), 2018.
Recurso online
  1. Link, Wolfgang. Components and regulation of nuclear transport processes. 2015. http://www.yada-yada.co.uk/Blackwell/PAI/Audio/Wolfgang_Jan2015.mp3.
    10.1111/febs.13163
Resumo em conferência
  1. João G. N. Sequeira; Link, Wolfgang; Machuqueiro, Miguel. Autor correspondente: João G. N. Sequeira. "HTVS protocol to identify non-covalent inhibitors of CRM1". Trabalho apresentado em Encontro de Jovens Investigadores de Biologia Computacional Estrutural, Coimbra, 2021.
    10.3390/mol2net-07-12108
  2. Barbosa-Mota, Júlio; Link, Wolfgang; De Sousa-Coelho, Ana Luísa. "Análise da expressão de TRIB2 em diferentes de pacientes diabéticos e modelos de diabetes em roedores.". Trabalho apresentado em 15º Congresso Português de Diabetes (Rev Port Diabetes), Vilamoura, 2019.
    Publicado
  3. De Sousa-Coelho, Ana Luísa; Rodrigues-Viegas, Vanessa; Link, Wolfgang. "Análise da expressão de TRIB2 em tecidos sensíveis à insulin associados à obesidade.". Trabalho apresentado em 15º Congresso Português de Diabetes (Rev Port Diabetes), Vilamoura, 2019.
    Publicado
Tese / Dissertação
  1. Raposo, Catarina Martins. "Study of the TRIB2 protein network". Mestrado, 2019. http://hdl.handle.net/10400.1/13375.
  2. Henriques, Vanessa Mendes. "Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK". Mestrado, 2017. http://hdl.handle.net/10400.1/10705.
  3. Santos, Marta Machado Pereira dos. "Characterization of TRIB2-mediated resistance to anti-cancer drugs". Mestrado, 2016. http://hdl.handle.net/10400.1/8442.
  4. Silva, Neuton Pedro Gorjão da. "TRIB2 confers resistance to MAPK and TOR1 inhibitors". Mestrado, 2016. http://hdl.handle.net/10400.1/9833.
  5. Baptista, Inês do Carmo Viegas. "Characterization of TRIB2 following PI3K inhibition". Mestrado, 2015. http://hdl.handle.net/10400.1/7684.
  6. Colaço, Laura Guerreiro. "Investigating the role and function of Tribbles 2 (TRIB2) in drug resistance within cancer". Mestrado, 2014. http://hdl.handle.net/10400.1/8366.

Propriedade Intelectual

Patente
  1. Link, Wolfgang; Pastor J. F.. 2012. "New amino-imidazolothiadiazole compound useful for treating e.g. cancer, cardiovascular disease, viral infection, inflammation, neurological disorder, bone disorder, atherosclerosis, pulmonary fibrosisrestenosis, stroke, diabetes".
    Concedida/Emitida
  2. Link, Wolfgang. 2003. "Caenorhabditis parkin gene and transgenic nematodes for use as Parkinson's disease models and for drug screening".
    Concedida/Emitida
  3. Link, Wolfgang. 2000. "Calcium-dependent transcriptional regulator DREAM and its cDNA and methods for drug screening".
    Concedida/Emitida

Outros

Empresa spin-off
  1. 2020. Refoxy Pharmaceuticals GMBH, Berlin/Boston. Drug Discovery. https://www.refoxy.com/.
  2. 2010. exCELLerate S.L.. Image-based Drug Discovery.
Outra produção
  1. Anti-cancer Drugs: Discovery, Development and Therapy. 2015. Wolfgang Link. https://doi.org/10.1007%2F978-3-319-21683-6_6.
    10.1007/978-3-319-21683-6_6
  2. Finding novel targets for anticancer therapy. 2010. Link, W.. http://www.scopus.com/inward/record.url?eid=2-s2.0-77953451665&partnerID=MN8TOARS.
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2023/10/24 Location, location, location: Protein localization in disease and therapy. , October 24/25th, 2023, Paris, France
French Government (Paris, França)
2023/10/17 Refoxy Pharma: Targeting FOXO3 to Repair. Restore. Rejuvenate. Round Table: Road to success in biotech and pharma companies,
PANDORA COST action IG17104
2023/07/12 Caught in the Nuclear Trap: Novel strategies to fight Cancer and Emerging Viruses by Nuclear Export Inhibition invited Talk
BioISI – Instituto de Biosistemas e Ciências Integrativas, Faculdade de Ciências, Universidade de Lisboa (Lisbon, Portugal)
2023/07/11 Principles of Cancer Treatment & Anticancer Drug Development, , 10th -12th of July 2023, Lisbon, Portugal
COST Pandora (Lisbon, Portugal)
2023/06/13 Targeting FOXO: Everything Everywhere All at Once
CSIC (Miraflores, Espanha)
2023/03/24 Caught in the Nuclear Trap: Novel strategies to fight Cancer and Emerging Viruses by Nuclear Export Inhibition, (Invited talk), March 24, 2023 at Algarve Biomedical Center Research Institute (ABC-RI), Faro, Portugal Invited Seminar
ABC-RI (Faro, Portugal)
2023/01/24 Discovery of novel targets and small molecule compounds for healthy aging and anticancer therapy, January 23 -25, 2023, Benidorm, Spain
CSIC (Benidorm, Espanha)
2022/09/29 High content imaging-based discovery of novel targets and small molecule compounds for healthy aging and anticancer therapy. (Invited talk). Jornada de usuarios de High Content Screening, 29th September 2022 at Instituto de Salud Carlos III, Centro Nacional de Microbiología, Majadahonda, Spain
2022/06/27 Understanding and Targeting the TRIB2-AKT-FOXO axis in human cancer and aging. III International Meeting of the Portuguese Society of Genetics, 27th and 28th June 2022 at the University of Évora, Portugal
2021/09/06 Emerging targets and small molecule drug candi-dates to overcome cancer therapy resistance, Invited talk, STRATAGEM, Annual conference 6th September 2021, Prague, Czech Republic STRATAGEM, Annual conference
STRATAGEM (Prague, República Checa)
2021/01/07 HTVS protocol to identify non-covalent inhibitors of CRM1, João Gonçalo Nunes Sequeira *, Wolfgang Link, Miguel Machuqueiro, MOL2NET'21, Conference on Molecular, Biomedical & Computational Sciences and Engineering, 7th ed., Chem-Bioinformatics Congress München, Germany-Chapell Hill, USA, 2021
2020/04/22 Tribbles pseudokinases in anti-cancer therapy resistance International Web Symposium, Pseudokinases and Tribbles - from Molecules to Therapy
Helmholtz Zentrum München, Germany (Madrid, Espanha)
2020/02/28 Targeting FOXO proteins to extend lifespan and fight cancer and anti-cancer drug resistance Invited talk, STRATAGEM, Annual conference 28th February 2020, Belgrade, Serbia STRATAGEM, Annual conference
COST (Belgrade, Sérvia)
2020/01/31 Spinning off academic discovery of FOXO - modulating compounds into small biotech companies TRANSAUTOPHAGY Translational Workshop
COST (Faro, Portugal)
2020/01/15 Harmine and Piperlongumine revert TRIB2-mediated drug resistance. Invited talk International Online Symposium on Synthesis and nanodelivery strategies for new therapeutic tools against Multidrug Resistant Tumours
COST STRATAGEM (Madrid, Espanha)
2019/09/20 Targeting the TRIB2 - FOXO axis of anti-cancer drug resistance; September 20, Invited Talk at General, Hospital of Vienna, Austria. Stratagem WG meeting
General Hospital of Vienna (Vienna, Áustria)
2019/06/07 Targeting FOXO proteins to fight cancer and extend lifespan; IIBM seminar, June 7, Madrid, Spain Seminar Cycle
IIBM (Madrid, Espanha)
2019/04/12 Tribbles proteins determine the level of activity of the oncokinase AKT Jornadas Liga Portuguese Contra o Cancro
Liga Portuguese Contra o Cancro, IPOLFG (Lisbon, Portugal)
2019/03/26 High content screening-based discovery of natural products from microalgae to treat cancer and slow aging, I Seminário Projeto ALGARED+, March 26, Faro, Portugal Seminário Projeto ALGARED+
CCMAR (Faro, Portugal)
2018/12/13 Targeting FOXO proteins to fight cancer and extend lifespan. “Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery” Conference, December 13, 2018, La Laguna, Tenerife, Spain Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery” Conference
COST (tenerife, Espanha)
2018/10/16 TRIB2-mediated activation of AKT confers resistance to anti-cancer therapy, International workshop on The cell biology behind the ONCOGENIC PIP3 LIPIDS October 16, 2018, Baeza, Spain International workshop on “The cell biology behind the ONCOGENIC PIP3 LIPIDS
Universidad Internacional de Andalucía - Sede Antonio Machado de Baeza (Baeza, Espanha)
2018/05/29 Targeted strategies for the discovery of chemical compounds with therapeutic potential against cancer, Universidad de La Laguna, Instituto de Productos Naturales y Agrobiología del CSIC, May 29,2018, Tenerife, Spain Seminar
Universidad de La Laguna, Instituto de Productos Naturales y Agrobiología del CSIC (La laguna, Espanha)
2018/05/08 TRIB2 acts as a major driver of tumorigenesis and anti-cancer drug resistance 2th International Symposium on “TRIBBLES and Diseases"
TRIBBLES Network (Beijing, China)
2018/04/18 Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitors in the context of melanoma III Jornadas Liga Portuguese Contra o Cancro
Liga Portuguese Contra o Cancro (Lisbon, Portugal)
2018/03/03 Targeted drug discovery for Precision Oncology 5th MC/WG Meeting
COST Action CM1407 (Salini Resort, Malta)
2017/06/06 Characterization of TRIB2 mediated resistance to anti-melanoma drugs II Jornadas de Investigação em Oncologia em Portugal
IPOLFG (Lisbon, Portugal)
2017/05/19 Means to restore tumor suppressor genes in pancreatic cancer 2nd Porto Precision OONCOLOGY Meeting
IPATIMUP (Porto, Portugal)
2017/05/08 TRIB2, FOXO and p53: The evil axis of anti-cancer drug resistance 8th Meeting on Signal Transduction
SINAL (Lisbon, Portugal)
2017/03/03 FOXO Caught in the Crosshairs: Discovering Targets and Drugs for Innovative Anti-Cancer Therapies COST Annual Meeting
Jagiellonian University (Krakow, Polónia)
2016/10/06 TRIB2, FOXO and p53: The evil axis of anti-cancer drug resistance Invited seminar
University of Sheffield, Medical School, Sheffield (Sheffield, Reino Unido)
2016/06/18 FOXO Caught in the Crosshairs: Strategies of Innovative Drug Discovery Invited Seminar
CCMAR (faro, Portugal)
2016/06/08 TRIB2 as an oncogenic FOXO suppressor protein Tribbles Proteins at the Interface of Metabolism and Cancer
TRIBBLES network (Faro, Portugal)
2016/04/04 Discovering ways to tackle cancer drug resistance Invited seminar
IIBM-CSIC (Madrid, Espanha)
2016/02/12 TIBBLES breaking bad: TRIB2 confers resistance to anti-cancer drugs Invited seminar
IdiPAZ Madrid (Madrid, Espanha)
2015/04/23 TRIB2 acts as an oncogene in melanoma and confers drug resistance by deregulating the AKT signalling network Biochemical Society Conference, Tribbles at the crossroads of metabolism, cancer, immunity and development
Biochemical Society (Budapest, Hungria)
2014/10/14 Translocation in Cancer Therapy CIBICAN Conference on Molecular Pharmacology and Mechanisms of New Anticancer Drugs
CIBICAN (Tenerife, Espanha)
2013/07/05 Targeting the subcellular localization of tumor suppressors and oncogenic proteins as anti-cancer therapy Invited seminar
Fundación Medina, University of Granada (Granada, Espanha)
2013/06/21 FoxO Proteins as Potential Targets for Anti-Cancer Therapy FOXO3 and Related Transcription Factors in Development, Aging and Exceptional Longevity
Longevity Consortium, US (San Francisco, Estados Unidos)
2012/07/04 Exploring the spatio-temporal regulation of disease-relevant proteins for the development of anti-cancer therapies Invited Seminar
Universita degli Studi di Milano (Milan, Itália)
2012/04/14 Exploring the spatio-temporal regulation of disease-relevant proteins for the development of anti-cancer therapies SINAL2012, 6th National Meeting on Cell Signaling, University of Minho
SINAL (Braga, Portugal)
2012/03/16 Protein localization in disease and therapy 3rd Scientific Meeting of Institute for Biotechnology and Bioengineering Instituto Superior Técnico
Instituto Superior Técnico (Lisbon, Portugal)
2011/07/07 Protein localization in disease and therapy Invited seminar
nstitute for Biotechnology Bioengineering Dep. Ciências Biomédicas e Medicina, Universidade do Algarve (Faro, Portugal)
2011/06/14 Exploring the spatio-temporal regulation of disease-relevant proteins for the development of therapeutic strategies Invited seminar
Institut de Recerca, Hospital Universitari Vall d'Hebron
2011/05/24 Pathway-oriented target and drug discovery for anticancer therapy Invited seminar
UKE Eppendorf, University Hamburg (Hamburg, Alemanha)
2011/05/17 Mislocalization and therapeutic restoration of normal protein localization in human diseases BD Biosciences Meeting
University Heidelberg (Heidelberg, Alemanha)
2010/06/24 High content imaging-based discovery of novel targets and small molecule inhibitors for anticancer therapy 2nd Annual Cellular Imaging Analysis,
Trinity College (Dublin, Irlanda)
2010/02/11 Image based pathway analysis of FOXO regulation leads to the discovery of therapeutic targets and small molecule inhibitors for anticancer therapy 22nd Lorne Cancer Conference
Lorne Cancer (Lorne, Austrália)
2009/10/21 A hierarchical network of image based screens and counter screens to explore strategies for restoring FOXO activity in human cancer 5th annual Global Imaging Summit
Global Imaging (Berlin, Alemanha)
2009/06/22 Exploring the Biological Space of FOXO Transcription Factors: Discovery of Kinase Inhibitors for Anticancer Therapy BIT's Annual World Cancer Congress
BTI (Beijing, China)
2008/09/10 Large-scale cell biology – Tackling the complexity of biological systems Invited Seminar
Centro Nacional de Investigaciones Cardiovasculares (CNIC) (Madrid, Espanha)
2008/08/02 Using High Content Cellular Imaging to crack the FOXO Code 4th annual Global Imaging Summit
GIS (cologne, Alemanha)
2008/07/09 Hunting with the Fox – Loss of Function screen identifies suppressors of FoxO function Informa´s MicroRNA & RNAi Industry Summit
Informa (London, Reino Unido)
2008/06/12 Screening for Content - Image-based Anticancer Drug Discovery BIT's Annual World Cancer Congress
BIT (Shanghai, China)
2008/03/11 Cellular pathway analysis using High-Content Imaging Informa´s 2nd annual High Content Analysis
Informa (berlin, Alemanha)
2008/03/06 High-Content Screening of complex RNAi and Compound libraries Invited seminar
University of Bergen (Bergen, Noruega)
2008/02/05 Screening for Content - Image-based Anticancer Drug Discovery Personalised Medicine Partnerships in Oncology & Cardiology
Next Level Pharma (Munich, Alemanha)
2008/01/09 Chemical genetic approach to study the regulation of nuclear-cytoplasmic shuttling of FoxO using High-Content Imaging CHI´s Fifth Annual High Content Analysis
CHI (San Francisco, Estados Unidos)
2007/06/29 Applying the Power of High Content Screening to Anti-Cancer Drug Discovery Invited Seminar
Centro de Investigación Príncipe Felipe (CIPF)
2007/06/27 High Content Screening-based Drug Discovery Informa´s High Content Analysis
Informa (Vienna, Áustria)
2007/06/08 An image-based approach to screen for inhibitors of the PI3K/Akt signaling pathway X Congreso de la Sociedad Ibérica de Citometría (SIC)
Sociedad Ibérica de Citometría (valencia, Espanha)
2006/09/29 Pathway specific anti-cancer drug discovery: Identification of therapeutic targets associated with PI3K/Akt signalling. Screening Europe
SEN (Prague, República Checa)
2006/09/26 Applying the Power of High Content Screening to Anti-Cancer Drug Discovery Invited Seminar
Institute for Research in Biomedicine (IRB) (Barcelona, Espanha)
2004/09/22 Development of cell - based high throughput assays targeting the PI3´K/Akt pathway for anti-cancer drug discovery III jornadas oncológicas CIC Apoptosis y Cáncer
CIC (Salamanca, Espanha)
2003/09/06 Day-Night changes in DREAM activity contribute to circadian gene expression in pineal gland X Congreso de la Sociedad Española de Neurosciencias
Sociedad Española de Neurosciencias (Lerida, Espanha)

Orientação

Título / Tema
Papel desempenhado 		Curso (Tipo)
Instituição / Organização
2017/04/01 - Atual Characterizing the role of FOXO regulators and FOXO isoforms in cancer
Coorientador
Universidade do Algarve, Portugal
2021/04/01 - 2022/03/31 TRIB2 regulation in melanoma.
Orientador
Instituto de Investigaciones Biomédicas Sols-Morreale, Espanha
2019/09/01 - 2021/01/29 Descoberta de moduladores de FOXO para tratamentos anticancerígenos e antienvelhecimento
Coorientador
 Master
Universidade do Algarve, Portugal
2019/11/01 - 2020/12/31 GENERATION OF DRUG-RESISTANT CELL LINES AS A MODEL TO STUDY PANCREATIC CANCER
Coorientador
Universidade do Algarve, Portugal
2019/09/01 - 2020/11/30 THERAPEUTIC STRATEGIES TARGETING FOXO TRANSCRIPTION FACTORS
Orientador
Instituto de Investigaciones Biomédicas Sols-Morreale, Espanha
2016/09/01 - 2020/11/19 CHARACTERIZATION OF TRIB2-MEDIATED DRUG RESISTANCE
Coorientador de SUSANA DA COSTA SILVA MACHADO
Universidade do Algarve, Portugal
2019/04/01 - 2020/03/31 THERAPEUTIC STRATEGIES TARGETING FOXO TRANSCRIPTION FACTORS
Orientador
Instituto de Investigaciones Biomédicas Sols-Morreale, Espanha
2018/02/01 - 2019/02/22 Descoberta de moduladores de FOXO para tratamentos anticancerígenos e antienvelhecimento
Coorientador
Universidade do Algarve, Portugal
2017/09/01 - 2018/06/30 Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK
Orientador
Universidade do Algarve - Campus de Gambelas, Portugal
2017/03/03 - 2018/05/16 Analysis of TRIB2 expression levels in insulin-sensitive tissues to unraveling TRIB2’s role in metabolism
Coorientador
Universidade do Algarve, Portugal
2016/09/01 - 2017/10/15 Study of the TRIB2 protein network
Orientador
2014/09/01 - 2015/07/04 Characterization of TRIB2 following PI3K inhibition
Orientador
Universidade do Algarve - Campus de Gambelas, Portugal
2014/09/01 - 2015/06/30 Characterization of TRIB2-mediated resistance to anti-cancer drugs
Orientador
Universidade do Algarve - Campus de Gambelas, Portugal
2014/09/01 - 2015/06/30 TRIB2 confers resistance to MAPK and mTOR1 inhibitors
Orientador
Universidade do Algarve - Campus de Gambelas, Portugal
2013/09/01 - 2014/06/30 Investigating the role and function of Tribbles 2 (TRIB2) in drug resistance within cancer
Orientador
Universidade do Algarve - Campus de Gambelas, Portugal
2005/12/01 - 2009/05/08 Development of Technological Platforms for the identification of Novel Cellular Modulators of FOXO activity
Orientador de Fábian Zanella de Sá
Centro Nacional de Investigaciones Oncológicas, Espanha

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação) 		Instituição / Organização
2022/06/29 - Atual Webinar Organizer and Chair with invited speaker Robert A. Weinberg (USA) Whitehead Institute for Biomedical Research with over 300 participants on 29 June 2022 (2022/06/06)
2022/12/16 - 2022/12/16 Online Panel Discussion with Vera Gorbunova (USA) and Joris Deelen (Germany), Decoding the genetic secrets of extreme longevity. December 16th, 2022 (2022/12/16)
2020/01/30 - 2020/01/31 2nd Joint WG4-WG5 TRANSAUTOPHAGY, Faro/Portugal (2020/01/30 - 2020/01/31)
Congresso (Coorganizador)
2016/06/08 - 2016/06/09 International Meeting: ¿Tribbles Proteins at the Interface of Metabolism and Cancer (2016/06/08 - 2016/06/09)
Congresso (Presidente da Comissão Organizadora)
 Universidade do Algarve - Campus de Gambelas, Portugal
2010/10/04 - 2010/10/05 BD Pathway Users Workshop (2010/10/04 - 2010/10/05)
Oficina (workshop) (Presidente da Comissão Organizadora)
2007/03/26 - 2007/03/27 High Content Analysis, Spain, 2007 (2007/03/26 - 2007/03/27)
Congresso (Presidente da Comissão Organizadora)
 Centro Nacional de Investigaciones Oncológicas, Espanha

Arbitragem científica em conferência

Nome da conferência Local da conferência
2018/09/21 - 2018/09/22 SINAL, 9th Meeting on Signal Transduction SINAL

Comissão de avaliação

Descrição da atividade
Tipo de assessoria 		Instituição / Organização Entidade financiadora
2019/10/01 - Atual TubInTrain Member of the international Evaluation Board of TubInTrain, European Joint Doctorate on chemistry and biology and focused on the microtubules breakdown (www.tubintrain.eu).

Consultoria / Parecer

Descrição da atividade Instituição / Organização
2019/10/01 - Atual Expert advisor for European FET Expert, Trendington; Prefet. Defining topics for European FET call
2001/03/01 - Atual Expert advisor for pharmaceutical industry Supervisor, Analysis of PI3K mutants for Eli Lilly, Indianapolis, EE UU Advisor, Consulting for Consorcio NanoFarma de vehiculización de fármacos (Drug delivery), project CENIT, Spain Advisor, Consulting for Bayer Pharma AG targeting Drug Resistance in Cancer Advisor, Apollo Ventures, funding anti-aging companies

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2006/10/01 - Atual Lecturer, PhD Course, University of Valencia (UV) Co-cordinator, Course on high content imaging, CNIO/Madrid Lecturer, Master Biotechnology, University of Barcelona (UB) Lecturer, ANGIOKEM, Rhodes, Greece Lecturer, Master Biotechnology, (UB) Lecturer, Master Biomedicine, UAlg Professor, Problem-based learning Medicine, UAlg Lecturer, Undergraduate Courses in Human genetics, UAlg Co-coordinator, Master Course Oncobiology, UAlg Lecturer, Signal Transduction, Cancer Therapy, Master Course, UAlg Lecturer, ESCCA Summer School (UV)

Outro júri / avaliação

Descrição da atividade Instituição / Organização
2012/03/11 - Atual EVALUATION FOR RESEARCH FUNDING ORGANISATIONS Austrian Science Fund (ASF, Austria) Dutch Cancer Society (Netherlands) European Research Council (European Union) FCT and Fundo iMM Laço (Portugal) Health Research Council New Zealand Italian Ministry of Health and Agenzia Italina del Farmaco (Italy) North West Cancer Research, Leuka and the Brain Tumour Charity (UK) Spanish Agency of Evaluation and Assessment (Spain) University of Cape Town (South Africa) University of Macau (China)
2012/03/01 - Atual PARTICIPATION IN INTERNATIONAL NETWORKS COST Action: CM1106, Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells COST Action: BM1204, An integrated European platform for pancreas cancer research: from basic science to clinical and public health interventions for a rare disease COST Action: CM1407, Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery Longevity Consortium, US (www.longevityconsortium.org)
2009/01/01 - Atual JOURNAL REVIEWER FOR (selected list) Biochemical J., Cancers, Carcinogenesis, ChemBioChem, Chemical Reviews, Current Medicinal Chemistry, Current Molecular Medicine, Drug Discovery Today, European Journal of Pharmacology, FEBS Letters, Frontiers in Immunology, Hepatology, J Cell Biochem, J Cell Science, J Cellular and Molecular Medicine, Medical Research Reviews, Nature Chemical Biology, Nature Comm., Neoplasia, Oncogene, Oncology Letters, Oral OncologyPloS ONE, PNAS, Redox Biology, Scientific Reports, Theranostics, Trends Cell Biology
2010/01/01 - 2020/12/31 JOURNAL REVIEWER FOR: Oxidative Medicine and Cellular Longevity, PloS ONE, PNAS, Redox Biology, Rejuvenation Research, Scientific Reports, SpringerPlus, Targeted Oncology, Trends Cell Biology, WJBC, World Journal of Medicine and Medical Science Research
2010/01/01 - 2020/03/31 JOURNAL REVIEWER FOR: Analytical Chemistry, Apoptosis, BBA - Molecular Basis of Disease, Biochemical J., Biotechniques, Biotechnology J, BMC Cell Biology, Cancer Drug Resistance, Carcinogenesis, ChemBioChem, Chemical Research in Toxicology, Chemical Reviews, Cellular Signalling, Current Medicinal Chemistry, Current Molecular Medicine, Cytometry A, Drug Discovery Today, EBioMedicine, European Journal of Pharmacology, Expert Opinion On Drug Discovery, F1000_Faculty Reviews, FEBS Letters, Gene, Gynecologic Oncology, Hepatology
2010/01/01 - 2020/03/31 JOURNAL REVIEWER FOR: International Journal of Cancer, Internat J Developmental Neurosci, International Journal of Oncology, J Biomol Screening, J Cell Biochem, J Cell Science, J Gastrointestinal and Liver Diseases, J Hematology & Oncology, J Inorg Biochem, Journal of Visualized Experiments, Life Sciences, Medical Research Reviews, Micromachines, Molecular Biology Reports, Molecular Imaging, Molecules, Nature Chemical Biology, Nature Comm., Neoplasia, Neuroscience Letters, Oncogene, Oncology Letters, Oncology Reports, Oncotarget, Oral Oncology
Distinções

Prémio

2023 Prémio Ensino e Aprendizagem UAlg 2022/23 - Professor do Ano distinguido pelos Estudantes
Universidade do Algarve, Portugal

Título

2000 PhD
Universität Hamburg, Alemanha